MedPlus Health Services Subsidiary Faces Drug License Suspension in Karnataka
MedPlus Health Services Limited disclosed that its subsidiary Optival Health Solutions Private Limited received a five-day drug license suspension order from Karnataka's Drug Control Administration for a store at Ganganagar Bus Stop. The suspension, effective from December 10, 2025, was issued under the Drugs and Cosmetics Act and Rules, with the company estimating a potential revenue loss of ₹2.40 lacs during this period.
*this image is generated using AI for illustrative purposes only.
MedPlus Health Services Limited has disclosed a regulatory development affecting one of its subsidiaries through a filing with stock exchanges on December 11, 2025. The company informed BSE Limited and National Stock Exchange of India Limited about a drug license suspension order received by its subsidiary Optival Health Solutions Private Limited.
Regulatory Action Details
The suspension order was issued by the Assistant and Director of Drug Control Administration, Bangalore Circle-5, Karnataka, targeting a specific store location. The affected store is situated at Ganganagar Bus Stop in Karnataka.
| Parameter: | Details |
|---|---|
| Issuing Authority: | Assistant and Director, Drug Control Administration, Bangalore Circle-5 |
| Nature of Action: | Drug License Suspension |
| Duration: | Five days |
| Store Location: | Ganganagar Bus Stop, Karnataka |
| Order Received Date: | December 10, 2025 |
Legal Framework and Compliance
The suspension order was issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. This regulatory framework governs the licensing and operation of pharmaceutical retail establishments across India.
Financial Impact Assessment
The company has quantified the potential financial impact of this regulatory action. MedPlus Health Services estimates a potential revenue loss of ₹2.40 lacs resulting from the five-day suspension period.
| Impact Category: | Amount |
|---|---|
| Potential Revenue Loss: | ₹2.40 lacs |
| Duration: | Five days |
Disclosure and Transparency
The disclosure was made pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. The company has ensured that this information will be available on its website at www.medplusindia.com , as well as on the websites of both stock exchanges.
The filing was signed by Manoj Kumar Srivastava, Company Secretary and Compliance Officer, demonstrating the company's commitment to regulatory compliance and transparent communication with stakeholders regarding material developments affecting its operations.
Historical Stock Returns for Medplus Health Services
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.06% | -1.92% | +1.75% | -7.78% | -5.23% | -28.55% |
19
